Razionale:
Breast cancer represents the most frequent malignancy in the female sex and the leading cause of cancer-related death in women. Recent years have been marked by major advances in the treatment of metastatic disease that have led to a significant improvement in survival, thanks to a strategy increasingly focused on personalization.
In particular, scientific advances in HER2+ disease have improved outcomes for these patients but increased survival remains a primary goal for metastatic stage patients.
The goal of this project is, in addition to scientific updates on the possibilities offered by new treatment options, to identify what issues need to be addressed within the care pathway of metastatic HER2+ patients in order to understand how to optimize their management by sharing experiences from diverse and international clinical settings.
Indeed, the management of HER2+ metastatic patients requires an integrated approach that takes into account the complexity of the disease and involves a variety of professionals and tools, such as RWE (real world evidence) and SDM (shared decision making), to ensure the best possible outcome in terms of survival and well-being.